Ongoing clinical development study confirms Lifecare's expectation of a sensorlongevity that far exceeds the lifetime of existing and commercially availableneedle sensors for glucose monitoring. Today Lifecare can report that sensors used in a three-day clinical studycontinue to work in an in vitro set up, showing an operational longevity for atotal of 4 weeks and still ongoing. The current clinical trial sensor is not the final product, but it alreadyrepresents a major step forward for Lifecare's Sencell-technology. - We have 20people in our outstanding team who have worked intensively to achieve theseresults and everyone is thrilled to see the outcome, says CEO Joacim Holter. Lifecare is developing a Continuous Glucose Monitoring (CGM) sensor at the sizeof a grain of rice, with an expected longevity exceeding those of existingneedle based CGM-systems. Lifecares sensor is currently subject to thefirst-in-human studies. Longevity Lifecare CSO Prof. Andreas Pfützner describes the results as a breakthrough forthe product development of the sensor technology. - Now we have a first proofthat a sensor employing the miniaturized core Sencell technology has beenoperational in the human body for several days continues to work in an in vitroset-up for more than 4 weeks. This is not possible with a commercially availableneedle sensor. The in vitro set-up experiment will continue, with theexpectation that we can confirm additional longevity in the months to follow. Beside the longevity, the study provides already strong indications that ourtechnology is at least as accurate and may be superior to commercially availableneedle sensors. Our study is also an indication of the robustness of the sensingtechnology - you can basically take the sensor in and out of the body and itcontinues to measure correctly. - The study shows the stability and robustness of our technology, says Prof.Pfützner, - and it is an indication that Lifecare is in the process of reachingthe planned long term of longevity. - As previously communicated, we have prolonged our technology development studyto clear out issues, improve the product, improve the performance of theproduct, and improve the longevity of the product, summarizes Joacim Holter. The current status of the development study firmly confirms the groundbreakingpotential of the Sencell technology. This is Lifecare Lifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).
Further informationJoacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40
This information is considered to be inside information pursuant to the EUMarket Abuse Regulation and is subject to the disclosure requirements pursuantto Section 5-12 the Norwegian Securities Trading Act. This stock exchangeannouncement was published by Joacim Holter, CEO at Lifecare AS, on 6 February2023 at 08:35 CET